Recent lines of clinical studies showed that neutrophils and neutrophil extracellular traps (NETs) influence the efficacy, safety, and outcomes of recombinant tissue-type plasminogen activator (rtPA) treatment in AIS [15], by causing physical obstruction-induced no-reflow [16], reperfusion resistance [17], and hemorrhagic transformation [18]. This evidence concerns the gene PLAT and androgen insensitivity syndrome.